These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 31995662)

  • 1. Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m).
    Marshall A; Levine M; Hill C; Hale D; Thirlwall J; Wilkie V; French K; Kakkar A; Lokare A; Maraveyas A; Chapman O; Arif A; Petrou S; Maredza M; Hobbs R; Dunn JA; Young AM
    J Thromb Haemost; 2020 Apr; 18(4):905-915. PubMed ID: 31995662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
    Robertson L; Yeoh SE; Ramli A
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
    Young AM; Marshall A; Thirlwall J; Chapman O; Lokare A; Hill C; Hale D; Dunn JA; Lyman GH; Hutchinson C; MacCallum P; Kakkar A; Hobbs FDR; Petrou S; Dale J; Poole CJ; Maraveyas A; Levine M
    J Clin Oncol; 2018 Jul; 36(20):2017-2023. PubMed ID: 29746227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OC-11 - Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism.
    Young A; Phillips J; Hancocks H; Hill C; Joshi N; Marshall A; Grumett J; Dunn JA; Lokare A; Chapman O
    Thromb Res; 2016 Apr; 140 Suppl 1():S172-3. PubMed ID: 27161683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
    Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
    JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
    Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
    Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
    Planquette B; Bertoletti L; Charles-Nelson A; Laporte S; Grange C; Mahé I; Pernod G; Elias A; Couturaud F; Falvo N; Sevestre MA; Ray V; Burnod A; Brebion N; Roy PM; Timar-David M; Aquilanti S; Constans J; Bura-Rivière A; Brisot D; Chatellier G; Sanchez O; Meyer G; Girard P; Mismetti P;
    Chest; 2022 Mar; 161(3):781-790. PubMed ID: 34627853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dalteparin and Rivaroxaban Sequential Use in Cancer Patients with Venous Thromboembolism.
    Chen L; Chen Q; Zhu M; Zhuang Z
    J Coll Physicians Surg Pak; 2021 Mar; 31(3):294-297. PubMed ID: 33775018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monotherapy Anticoagulation to Expedite Home Treatment of Patients Diagnosed With Venous Thromboembolism in the Emergency Department: A Pragmatic Effectiveness Trial.
    Kline JA; Adler DH; Alanis N; Bledsoe JR; Courtney DM; d'Etienne JP; Diercks DB; Garrett JS; Jones AE; Mackenzie DC; Madsen T; Matuskowitz AJ; Mumma BE; Nordenholz KE; Pagenhardt J; Runyon MS; Stubblefield WB; Willoughby CB
    Circ Cardiovasc Qual Outcomes; 2021 Jul; 14(7):e007600. PubMed ID: 34148351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer.
    Lee JH; Hyun DG; Choi CM; Lee JC; Kim WS; Oh YM; Lee SD; Lee JS
    Respiration; 2019; 98(3):203-211. PubMed ID: 31096241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients with Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study.
    Lu K; Liao QQ; Zhu KW; Yao Y; Cui XJ; Chen P; Bi Y; Zhong M; Zhang H; Tang JC; Yu Q; Yue JK; He H; Zhu ZF; Cai ZZ; Yang Z; Zhang W; Dong YT; Wei QM; He X
    Adv Ther; 2024 Jan; 41(1):391-412. PubMed ID: 37987918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical outcomes of different doses of rivaroxaban in patients with isolated distal deep vein thrombosis.
    Wang B; Wang Q; Ji Y; Zhang Y; Qiao T
    J Vasc Surg Venous Lymphat Disord; 2024 Mar; 12(2):101653. PubMed ID: 37490950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
    Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
    Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism.
    de Jong LA; van der Velden AWG; Hulst MV; Postma MJ
    BMJ Open; 2020 Nov; 10(11):e039057. PubMed ID: 33444193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
    Robertson L; Strachan J
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct oral anticoagulants for extended treatment of venous thromboembolism: insights from the EINSTEIN CHOICE study.
    Imberti D; Pomero F; Mastroiacovo D
    Blood Transfus; 2020 Jan; 18(1):49-57. PubMed ID: 31184579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.